Investigating a new target for treating prostate cancer growth
A novel determinant of prostate cancer growth
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-11047563
This study is looking at how a protein called citron kinase affects the growth of prostate cancer cells, with the hope of finding new treatment options that could help patients with advanced prostate cancer live longer and healthier lives.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-11047563 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a specific protein, citron kinase (CIT), influences the growth of prostate cancer cells. By exploring the mechanisms that control CIT expression and its role in aggressive cancer behavior, the researchers aim to develop new treatment strategies that can bypass the limitations of current therapies. The study will involve laboratory experiments to test the therapeutic potential of targeting CIT in prostate cancer. If successful, this research could lead to innovative treatments that improve survival rates for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with advanced prostate cancer who have not responded well to existing therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not been diagnosed with prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with advanced prostate cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting specific proteins for cancer treatment, suggesting that this approach could be effective.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HEEMERS, HANNELORE — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: HEEMERS, HANNELORE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced prostate cancer, anti-cancer therapy